This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kitahara, K. Articles by Noda, M. Search for Related Content PubMed PubMed Citation Articles by Kitahara, K. Articles by Noda, M.

Osteopontin Deficiency Induces Parathyroid Hormone Enhancement of Cortical Bone Formation

Department of Molecular Pharmacology (K.K., M.I., K.T., A.N., M.N.), Medical Research Institute, Tokyo Medical and Dental University, Tokyo 101-0062, Japan; Department of Cell Biology and Neuroscience (S.R.R.D.T.D.), Rutgers University, Piscataway, New Jersey 08854; and Department of Orthopedics (H.K.), Juntendo University, School of Medicine, Tokyo 113-8421, Japan

Address all correspondence and requests for reprints to: Masaki Noda, Department of Molecular Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, 3-10, Kanda-Surugadai 2-chome, Chiyoda-ku, Tokyo 101-0062, Japan. E-mail: noda.mph{at}mri.tmd.ac.jp.

Intermittent PTH treatment increases cancellous bone mass in osteoporosis patients; however, it reveals diverse effects on cortical bone mass. Underlying molecular mechanisms for anabolic PTH actions are largely unknown. Because PTH regulates expression of osteopontin (OPN) in osteoblasts, OPN could be one of the targets of PTH in bone. Therefore, we examined the role of OPN in the PTH actions in bone. Intermittent PTH treatment neither altered whole long-bone bone mineral density nor changed cortical bone mass in wild-type 129 mice, although it enhanced cancellous bone volume as reported previously. In contrast, OPN deficiency induced PTH enhancement of whole-bone bone mineral density as well as cortical bone mass. Strikingly, although PTH suppressed periosteal bone formation rate (BFR) and mineral apposition rate (MAR) in cortical bone in wild type, OPN deficiency induced PTH activation of periosteal BFR and MAR. In cancellous bone, OPN deficiency further enhanced PTH increase in BFR and MAR. Analysis on the cellular bases for these phenomena indicated that OPN deficiency augmented PTH enhancement in the increase in mineralized nodule formation in vitro. OPN deficiency did not alter the levels of PTH enhancement of the excretion of deoxypyridinoline in urine, the osteoclast number in vivo, and tartrate-resistant acid phosphatase-positive cell development in vitro. These observations indicated that OPN deficiency specifically induces PTH activation of periosteal bone formation in the cortical bone envelope.

This article has been cited by other articles:

				N. Ono, K. Nakashima, S. R. Rittling, E. Schipani, T. Hayata, K. Soma, D. T. Denhardt, H. M. Kronenberg, Y. Ezura, and M. Noda Osteopontin Negatively Regulates Parathyroid Hormone Receptor Signaling in Osteoblasts J. Biol. Chem., July 11, 2008; 283(28): 19400 - 19409. [Abstract] [Full Text] [PDF]

				M. Scatena, L. Liaw, and C. M. Giachelli Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2302 - 2309. [Abstract] [Full Text] [PDF]

				M. Ishijima, K. Tsuji, S. R Rittling, T. Yamashita, H. Kurosawa, D. T Denhardt, A. Nifuji, Y. Ezura, and M. Noda Osteopontin is required for mechanical stress-dependent signals to bone marrow cells J. Endocrinol., May 1, 2007; 193(2): 235 - 243. [Abstract] [Full Text] [PDF]

				Y. Saita, T. Takagi, K. Kitahara, M. Usui, K. Miyazono, Y. Ezura, K. Nakashima, H. Kurosawa, S. Ishii, and M. Noda Lack of Schnurri-2 Expression Associates with Reduced Bone Remodeling and Osteopenia J. Biol. Chem., April 27, 2007; 282(17): 12907 - 12915. [Abstract] [Full Text] [PDF]

				I. C. Ozkurt, F. Q. Pirih, and S. Tetradis Parathyroid Hormone Induces E4bp4 Messenger Ribonucleic Acid Expression Primarily through Cyclic Adenosine 3',5'-Monophosphate Signaling in Osteoblasts Endocrinology, August 1, 2004; 145(8): 3696 - 3703. [Abstract] [Full Text] [PDF]